Travere Therapeutics, Inc. (17R.F)

17,30 0,00 (0,00%) Ab 07:39PM CEST. Markt geöffnet.

Travere Therapeutics, Inc.

3611 Valley Centre Drive
Suite 300
San Diego, CA 92130
United States
888 969 7879
https://www.travere.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 380

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Eric M. Dube Ph.D.	President, CEO & Director	1,3M	N/A	1973
Mr. Christopher Cline C.F.A.	Chief Financial Officer	660,41k	N/A	1985
Ms. Elizabeth E. Reed J.D.	Senior VP, General Counsel & Corporate Secretary	663,85k	N/A	1971
Dr. William E. Rote Ph.D.	Senior VP and Head of Research & Development	695,84k	N/A	1963
Mr. Peter Heerma	Chief Commercial Officer	690,57k	N/A	1972
Ms. Sandra Calvin	SVP, Corporate Controller & Chief Accounting Officer	N/A	N/A	1966
Ms. Naomi Eichenbaum	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Charlotte Smith	Senior Vice President of Public Affairs	N/A	N/A	N/A
Ms. Angela Giannantonio	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Casey Logan	Chief Business Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Corporate Governance

Travere Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 6, Vorstand: 3, Shareholderrechte: 3, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.